Way back in April, the Food and Drug Administration announced its intent to have all Rantidine products removed from the shelves. That included the extremely popular heartburn drug Zantac. Zantac what’s the well-known brand name Ranitidine product. The US Foods and Drug Administration acknowledged that all drug manufacturers remove any prescription or over-the-counter products that included ranitidine.
Now generic producers of Ranitidine who failed to inform the FDA of the use of the product also failed to remove their products from shelves. The US Department of Justice is now investigating Sanofi and GlaxoSmithKline. It appears that both generic manufacturers failed to disclose the present NMDA is there a generic heartburn product. Both contain a probable human carcinogen, and they did not notify appropriate government agencies. They also did not remove their products from shelves or cease production. Sanofi is under particular scrutiny as it is the current owner of the Zantac brand name.
In essence, Sanofi acknowledged the NDMA in Zantac and removed Zantac from shells and stop production in April. They conveniently forgot to mention that they also produced in generic ranitidine.
Sanofi, based in France, Reported that they received information about the US Department of Justice initiating an investigation on June 6th. GlaxoSmithKline which is stationed in England receive notice of the investigation on June 18th. It wasn’t until recently that both companies took initiative to file information about the Ranitidine investigations through corporate filings in line with expectations of the United States Securities and Exchange Commission.
In addition to the US Department of Justice investigating both companies for violations of the false claims act, both now have lawsuits from the state of New Mexico as well. New Mexico filed suit against those companies for violating the New Mexico unfair Practices Act, public nuisance, negligence, and false advertising. Contact our experienced mass tort attorneys today.